Периоперационная химиотерапия в режиме FLOT у больных операбельной аденокарциномой желудка и кардиоэзофагеального перехода (I–III тип по классификации SIEWERT). Опыт НМИЦ онкологии им. Н.Н. Блохинастатья
Аннотация:To date, gastric cancer patients still have a poor prognosis. Current endoscopic or surgical treatment modalities are
radical only for early gastric cancer (T1). Curability dramatically declines as tumor invasion progresses and lymph node
metastasеs appear. In Europe and North America, the 5 -year overall survival rate of patients with stage T2–4 cancer is
20 % [1]. Combination therapy for gastric cancer is being extensively studied to improve the treatment outcomes [2–6].
Currently, perioperative chemotherapy with FLOT regimen is the mainstay of resectable gastric cancer treatment in Eu-
rope. FLOT4-AIO randomized study has shown that the FLOT regimen was associated with significant increase in the
median overall survival (50 versus 35 months), disease-free survival (18 versus 30 months) and R0 resection rate compared
to ECF / ECХ regimen.
In this work we evaluated the efficacy and toxicity of perioperative FLOT regimen in patients with gastric cancer and
gastroesophageal junction cancer type I–III cT4aN0M0, cT1–4N + M0, using a prospective database of patients treated
at the N. N. Blokhin Russian Cancer Research Center.